In this study, we demonstrated the limit of detection of 0.05% to detect EGFR mutations in cfDNA from NSCLC patients in NGS, F-PHFA and ddPCR, which is comparable to aforementioned previous findings [16] and superior to the commercially available cobas®EGFR Mutation Test v2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.